A selection of the companies we support.
Advanced Prodrug Technologies
PharmaCytics’ proprietary platform technology improves PK properties of small molecules of both R&D and marketed compounds. PharmaCytics focuses on increasing the oral bioavailability and thereby turning a parenteral compound into an effective oral variant. The technology creates an NCE and may thus contribute to the life cycle management plans of companies.
For patients, this renders a drug with a preferred route of administration and with less side effects and higher efficacy. For society on a whole, it leads to a significant decrease in health care costs.
Cancer immunotherapy for solid tumors
CimCure develops a vaccination based immunotherapy directed against the tumor blood vessels that are common to most solid tumors.
CimCure raised a seed investment of € 5 million in June 2022. This seed round was led by Positron Ventures and joined by several other health investors. Together with the Dutch vaccine company Intravacc, CimCure will further advance its lead cancer vaccine into the clinical phase.